title: Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma.
abstract: OBJECTIVE
  Toll-like receptors (TLR) signaling has dual effect of promoting tumor progression and anti-cancer property. This study was designed to determine the effect of polyinosinic-polycytidilic acid (poly I:C), a TLR3 agonist, on the proliferation of oral cancer cells.
  
  
  METHODS
  Human oral squamous cell carcinoma cell lines, YD-10B and YD-8, were used. TLRs expression was examined by RT-PCR and IL-8 production by poly I:C was examined by ELISA. Cell proliferation was determined by MTT assay. Flow cytometry and Western blot analysis were performed to determine the molecular mechanism of poly I:C-induced cell death.
  
  
  RESULTS
  TLR3 was functionally expressed in YD-10B and YD-8 cells. Treatment of poly I:C inhibited the cell growth in a dose-dependent manner. Flow cytometry and Western blot analysis revealed that poly I:C induced apoptosis via a mitochondria-dependent pathway. In addition, combination treatment with poly I:C and paclitaxel more significantly inhibited cell proliferation compared with poly I:C or paclitaxel alone.
  
  
  CONCLUSIONS
  Poly I:C effectively inhibits oral cancer cell proliferation and can be considered as a candidate to improve the inhibitory effect of anti-cancer drugs.
authors.affiliation: Department of Biochemistry, College of Medicine, Konyang University, Daejeon, Korea.
authors.forename: Jong-Hwan
authors.initials: JH
authors.lastname: Park
authors.forename: Do-In
authors.initials: DI
authors.lastname: Jeon
authors.forename: Hyo-Eun
authors.initials: HE
authors.lastname: Yoon
authors.forename: Seong-Min
authors.initials: SM
authors.lastname: Kwon
authors.forename: Soo-A
authors.initials: SA
authors.lastname: Kim
authors.forename: Sang-Gun
authors.initials: SG
authors.lastname: Ahn
authors.forename: Jung-Hoon
authors.initials: JH
authors.lastname: Yoon
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D017024:Chemotherapy, Adjuvant / Q000379:methods; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009062:Mouth Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011070:Poly I-C / Q000008:administration & dosage*; D051196:Toll-Like Receptor 3 / Q000819:agonists*
chemical_list: D051196:Toll-Like Receptor 3; D011070:Poly I-C; D017239:Paclitaxel